On June 7, Aduhelm (aducanumab) became the first new treatment for Alzheimer’s disease to be approved by…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has pulled back the controversial and sweeping approval recently given to …
Aduhelm (aducanumab), approved for Alzheimer’s disease in the U.S., is most appropriate for people with mild cognitive impairment (MCI)…
The National Institute on Aging (NIA) has awarded a five-year grant worth up to $5 million to support a clinical…
For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment…
In a few days, the U.S. Food and Drug Administration (FDA) is expected to announce whether or not…
A draft report from the Institute for Clinical and Economic Review, known as ICER, found that there is insufficient evidence…
LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation…
A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational…
Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according…